Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder
Abstract
Aim: To examine hospitalization risk factors in antipsychotic-treated patients with schizophrenia, bipolar I disorder (BD-I) or major depressive disorder (MDD). Patients & methods: Using Truven Health MarketScan® Commercial, Medicaid and Medicare Supplemental data (01/01/2012–06/30/2016), logistic regression models were performed to identify risk factors for both psychiatric and all-cause hospitalization in three separate analyses. Results: Significant risk factors included prior hospitalization (schizophrenia: odds ratio [95% CI]: 2.83 [2.50–3.21; psychiatric]; 2.58 [2.31–2.87; all-cause]; BD-I: 2.42 [2.23–2.63]; 2.09 [1.96–2.23]; MDD: 2.81 [2.49–3.16]; 2.21 [2.03–2.40]), previous antipsychotic treatment (schizophrenia: 1.71 [1.52–1.93]; 1.31 [1.18–1.46]; BD-I: 1.33 [1.23–1.44]; 1.22 [1.14–1.30]; MDD: 1.31 (1.11–1.54); 1.17 (1.04–1.32) and substance abuse (schizophrenia: 1.42 [1.27–1.60]; 1.37 [1.23–1.53]; BD-I: 1.72 [1.58–1.86]; 1.61 [1.50–1.72]; MDD: 1.90 [1.68–2.15] and 1.55 [1.41–1.71]). Conclusion: Prior hospitalization, previous antipsychotic treatment and substance abuse were associated with increased hospitalization risk in schizophrenia, BD-I or MDD.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest
1.
The National Institute of Mental Health. Mental Illness [Internet]. Health Inf. - Stat (2017). www.nimh.nih.gov/health/statistics/mental-illness.shtml.
2.
Stovall J. Bipolar disorder in adults: epidemiology and pathogenesis [Internet] (2016). www.uptodate.com/contents/bipolar%C2%ADdisorder%C2%ADin%C2%ADadults%C2%ADepidemiology%C2%ADand%C2%ADpathogenesis/print?source=search_result&search=bipolar%20stovall&select%E2%80%A6.
3.
Naudet F, Maria AS, Falissard B. Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS ONE 6(6), e20811 (2011).
4.
Wright BM, Eiland EH, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy 33(3), 344–359 (2013).
5.
Bergeson JG, Kalsekar I, Jing Y, You M, Forbes RA, Hebden T. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics. Am. Health Drug Benefits 5(6), 379–386 (2012).
6.
Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics. Curr. Med. Res. Opin. 34(1), 41–47 (2018).
• In this head-to-head comparison that included recently approved long-acting injectables (LAIs), aripiprazole once-monthly was more effective than haloperidol- and risperidone-LAIs in reducing all-cause hospitalization.
7.
Porcelli S, Bianchini O, De Girolamo G, Aguglia E, Crea L, Serretti A. Clinical factors related to schizophrenia relapse. Int. J. Psychiatry Clin. Pract. 20(2), 54–69 (2016).
8.
Sartorius N, Gulbinat W, Harrison G, Laska E, Siegel C. Long-term follow-up of schizophrenia in 16 countries. A description of the International Study of Schizophrenia conducted by the World Health Organization. Soc. Psychiatry Psychiatr. Epidemiol. 31(5), 249–258 (1996).
9.
Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr. Bull. 24(1), 75–85 (1998).
10.
Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br. J. Psychiatry J. Ment. Sci. 184, 346–351 (2004).
11.
Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers: a review. PharmacoEconomics 26(2), 149–162 (2008).
12.
Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opin. Drug Deliv. 13(2), 253–264 (2016).
13.
Lang K, Federico V, Muser E, Menzin J, Menzin J. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia. J. Med. Econ. 16(8), 997–1006 (2013).
• This study of Medicaid and Commercial insurance patients with schizophrenia reported that previous nonadherence, newly starting antipsychotic therapy and previous hospitalization were significant predictors of nonadherence and hospitalization in these patient populations.
14.
van Dijk D, Koeter MWJ, Hijman R, Kahn RS, van den Brink W. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophr. Res. 137(1–3), 50–57 (2012).
15.
Innes H, Lewsey J, Smith DJ. Predictors of admission and readmission to hospital for major depression: a community cohort study of 52,990 individuals. J. Affect. Disord. 183, 10–14 (2015).
• This study found a number of factors increased the risk of a first admission (e.g., gender, income, being a heavy drinker, etc.); whereas, only older age (70+ years) and previous psychiatric-related (other than major depression) admission were statistically significant risk factors for readmission.
16.
Lin C-H, Chen W-L, Lin C-M, Lee M-D, Ko M-C, Li C-Y. Predictors of psychiatric readmissions in the short- and long-term: a population-based study in Taiwan. Clinics 65(5), 481–489 (2010).
• This study compared predictors of readmission during varying follow-up times with only two factors (patient age and hospital accreditation level) associated with different risk levels depending on time period after discharge.
17.
Pesa JA, Doshi D, Wang L, Yuce H, Baser O. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Curr. Med. Res. Opin. 33(4), 723–731 (2017).
18.
Weiden P, Glazer W. Assessment and treatment selection for ‘revolving door’ inpatients with schizophrenia. Psychiatr. Q. 68(4), 377–392 (1997).
19.
Haywood T, Kravitz H, Grossman L, Cavanaugh JJ, Davis J, Lewis DA. Predicting the ‘revolving door’ phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am. J. Psychiatry 152(6), 856–861 (1995).
• Using the schedule for affective disorders and schizophrenia along with a life events history, this study identified substance abuse and medication noncompliance as the most important factors related to hospitalization frequency.
20.
Kane JM, Sanchez R, Zhao J et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J. Med. Econ. 16(7), 917–925 (2013).
21.
Tiihonen J, Mittendorfer-Rutz E, Majak M et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29/823 patients with schizophrenia. JAMA Psychiatry 74(7), 686–693 (2017).
22.
Di Lorenzo R, Sagona M, Landi G, Martire L, Piemonte C, Del Giovane C. The Revolving Door Phenomenon in an Italian Acute Psychiatric Ward: a 5-year retrospective analysis of the potential risk factors. J. Nerv. Ment. Dis. 204(9), 686–692 (2016).
23.
Frick U, Frick H, Langguth B, Landgrebe M, Hübner-Liebermann B, Hajak G. The revolving door phenomenon revisited: time to readmission in 17′145 [corrected] patients with 37′697 hospitalisations at a German psychiatric hospital. PLoS ONE 8(10), e75612 (2013).
24.
Hoblyn JC, Balt SL, Woodard SA, Brooks JO. Substance use disorders as risk factors for psychiatric hospitalization in bipolar disorder. Psychiatr. Serv. 60(1), 50–55 (2009).
25.
Turkington A, Mulholland CC, Rushe TM et al. Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br. J. Psychiatry J. Ment. Sci. 195(3), 242–248 (2009).
26.
Ciudad A, Alvarez E, Bobes J, San L, Polavieja P, Gilaberte I. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr. Res. 108(1–3), 214–222 (2009).
27.
Gastal FL, Andreoli SB, Quintana MI, Almeida Gameiro M, Leite SO, McGrath J. Predicting the revolving door phenomenon among patients with schizophrenic, affective disorders and non-organic psychoses. Rev. Saude Publica. 34(3), 280–285 (2000).
28.
Raven MC, Doran KM, Kostrowski S, Gillespie CC, Elbel BD. An intervention to improve care and reduce costs for high-risk patients with frequent hospital admissions: a pilot study. BMC Health Serv. Res. 11, 270 (2011).
29.
Billings J, Mijanovich T. Improving the management of care for high-cost medicaid patients. Health Aff. 26(6), 1643–1654 (2007).
30.
Billings J, Dixon J, Mijanovich T, Wennberg D. Case finding for patients at risk of readmission to hospital: development of algorithm to identify high risk patients. BMJ 333(7563), 327 (2006).
31.
Bobo WV, Hoge CW, Messina MA, Pavlovcic F, Levandowski D, Grieger T. Characteristics of repeat users of an inpatient psychiatry service at a large military tertiary care hospital. Mil. Med. 169(8), 648–653 (2004).
32.
Stein BD, Pangilinan M, Sorbero MJ et al. Using claims data to generate clinical flags predicting short-term risk of continued psychiatric hospitalizations. Psychiatr. Serv. 65(11), 1341–1346 (2014).
33.
Hirschfeld RMA, Bowden CL, Gitlin MJ et al. Practice guideline for the treatment of patients with bipolar disorder (Revision). FOCUS J. Lifelong Learn. Psychiatry 1(1), 64–110 (2003).
34.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373–383 (1987).
35.
Agency for Healthcare Research and Quality. HCUP chronic condition indicator. Healthc. Cost Util. Proj. (2015). www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp.
36.
Hamilton JE, Passos IC, de Azevedo Cardoso T et al. Predictors of psychiatric readmission among patients with bipolar disorder at an academic safety-net hospital. Aust. N. Z. J. Psychiatry 50(6), 584–593 (2016).
• In this study using electronic medical records, factors associated with increased risk of readmission in patients with bipolar disorder included being uninsured, homelessness, having previous psychiatric hospitalizations and male gender.
37.
Woo YS, Bahk W-M, Jung Y-E et al. One-year rehospitalization rates of patients with first-episode bipolar mania receiving lithium or valproate and adjunctive atypical antipsychotics: readmission on lithium versus valproate. Psychiatry Clin. Neurosci. 68(6), 418–424 (2014).
38.
Patel NC, Crismon ML, Pondrom M. Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. J. Behav. Health Serv. Res. 32(4), 438–445 (2005).
39.
Lang K, Korn J, Muser E, Choi JC, Abouzaid S, Menzin J. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. J. Med. Econ. 14(2), 217–226 (2011).
40.
Jaracz J, Tetera-Rudnicka E, Kujath D et al. The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland. Pharmacol. Rep. 66(4), 613–617 (2014).
41.
Mura G. Schizophrenia: from epidemiology to rehabilitation. Clin. Pract. Epidemiol. Ment. Health. 8(1), 52–66 (2012).
42.
Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch. Gen. Psychiatry 64(5), 543 (2007).
43.
Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Arch. Gen. Psychiatry 62(10), 1097 (2005).
44.
Hung Y-Y, Chan H-Y, Pan Y-J. Risk factors for readmission in schizophrenia patients following involuntary admission. PLoS ONE 12(10), e0186768 (2017).
45.
Ayano G, Duko B. Relapse and hospitalization in patients with schizophrenia and bipolar disorder at the St Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia: a comparative quantitative cross-sectional study. Neuropsychiatr. Dis. Treat. 13, 1527–1531 (2017).
46.
Benjenk I, Chen J. Effective mental health interventions to reduce hospital readmission rates: a systematic review. J. Hosp. Manag. Health Policy 2, 45 (2018).
47.
Kripalani S, Theobald CN, Anctil B, Vasilevskis EE. Reducing hospital readmission: current strategies and future directions. Annu. Rev. Med. 65, 471–485 (2014).
48.
Pincus HA. Care transition interventions to reduce psychiatric re-hospitalizations. National Association of State Mental Health Program Directors, Alexandria, VA, USA. www.nasmhpd.org/sites/default/files/Assessment%20%233_Care%20Transitions%20Interventions%20toReduce%20Psychiatric%20Rehospitalization.pdf.
49.
Ascher-Svanum H, Zhu B, Faries DE et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 10, 2 (2010).
50.
Lin C-H, Chen M-C, Chou L-S, Lin C-H, Chen C-C, Lane H-Y. Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital. Psychiatry Res. 180(2–3), 74–79 (2010).
51.
Aro S, Aro H, Salinto M, Keskimäki I. Educational level and hospital use in mental disorders: a population-based study. Acta Psychiatr. Scand. 91(5), 305–312 (1995).
52.
Hamer M, Stamatakis E, Steptoe A. Psychiatric hospital admissions, behavioral risk factors, and all-cause mortality: The Scottish Health Survey. Arch. Intern. Med. 168(22), 2474 (2008).
53.
Alavi M, Baharlooei O, AdelMehraban M. Do psychosocial factors predict readmission among diabetic elderly patients? Iran. J. Nurs. Midwifery Res. 22(6), 460–464 (2017).
54.
DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 12(1), (2012). http://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-12-20.
55.
Khaykin E, Eaton WW, Ford DE, Anthony CB, Daumit GL. Health insurance coverage among persons with schizophrenia in the United States. Psychiatr. Serv. 61(8), 830–834 (2010).
Information & Authors
Information
Published In
Copyright
© 2018 Otsuka Pharmaceuticals.
History
Received: 5 September 2018
Accepted: 29 November 2018
Published online: 17 December 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0090
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Ana Rabasco, Jihoon Choi, Ilana Ladis, Sarah A. Arias, Lauren M. Weinstock, Ivan Miller, Edwin D. Boudreaux, Carlos A. Camargo, Brandon A. Gaudiano, Who's getting care? Acute treatment utilization following an emergency department visit among adults with major psychiatric disorders and suicidal thoughts and behaviors, Journal of Psychiatric Research, 10.1016/j.jpsychires.2026.03.040, 198, (175-181), (2026).
- Jiseun Lim, KwangHo Mun, BaegJu Na, YuJin Lee, Association of health screening participation with cardiovascular mortality and suicide in patients with schizophrenia and bipolar disorder, Social Psychiatry and Psychiatric Epidemiology, 10.1007/s00127-026-03078-4, (2026).
- Andrew J. Cutler, Hemangi R. Panchmatia, Alejandro G. Hughes, Noah S. Webb, Michael J. Doane, Rakesh Jain, Healthcare Resource Utilization 6 Months Before and After Olanzapine/Samidorphan Initiation: Real-World Assessment of Patients with Schizophrenia or Bipolar I Disorder, Advances in Therapy, 10.1007/s12325-025-03211-w, 42, 8, (3691-3707), (2025).
- Naomi Launders, Kate Dotsikas, Louise Marston, Gabriele Price, David P. J. Osborn, Joseph F. Hayes, The impact of comorbid severe mental illness and common chronic physical health conditions on hospitalisation: A systematic review and meta-analysis, PLOS ONE, 10.1371/journal.pone.0272498, 17, 8, (e0272498), (2022).
- Ismaeel Yunusa, Chengwen Teng, Ibraheem M. Karaye, Emily Crounse, Saud Alsahali, Nasim Maleki, Comparative Safety Signal Assessment of Hospitalization Associated With the Use of Atypical Antipsychotics, Frontiers in Psychiatry, 10.3389/fpsyt.2022.917351, 13, (2022).
- Mika Kallio, Jyrki Korkeila, Markus Malmberg, Jarmo Gunn, Päivi Rautava, Päivi Korhonen, Ville Kytö, Impaired long-term outcomes of patients with schizophrenia spectrum disorder after coronary artery bypass surgery: nationwide case–control study, BJPsych Open, 10.1192/bjo.2022.10, 8, 2, (2022).
- Xiaoli Niu, Phani Veeranki, Syvart Dennen, Carole Dembek, Kimberly Laubmeier, Yanmei Liu, G. Rhys Williams, Antony Loebel, Hospitalization risk among adults with bipolar I disorder treated with lurasidone versus other oral atypical antipsychotics: a retrospective analysis of Medicaid claims data, Current Medical Research and Opinion, 10.1080/03007995.2021.1897557, 37, 5, (839-846), (2021).
- Xiaoli Niu, Syvart Dennen, Carole Dembek, Kimberly Laubmeier, Yanmei Liu, Phani Veeranki, Michael Tocco, G. Rhys Williams, Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data, Current Therapeutic Research, 10.1016/j.curtheres.2021.100629, 94, (100629), (2021).
- Yoo Hyun Um, Tae-Won Kim, Ho-Jun Seo, Seung-Chul Hong, Sung-Min Kim, Ji-Hye Oh, Jong-Hyun Jeong, Predictors of 1-year rehospitalization in inpatients with bipolar I disorder treated with atypical antipsychotics, International Clinical Psychopharmacology, 10.1097/YIC.0000000000000318, 35, 5, (263-269), (2020).
- Tania Lecomte, Charles-Édouard Giguère, Briana Cloutier, Stéphane Potvin, Comorbidity Profiles of Psychotic Patients in Emergency Psychiatry, Journal of Dual Diagnosis, 10.1080/15504263.2020.1713425, 16, 2, (260-270), (2020).